Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic
innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic …

Glial cell-derived neurotrophic factor (GDNF), and the neurotrophin nerve growth factor
(NGF) and brain-derived neurotrophic factor (BDNF) are important for the survival …

Alzheimer′ s disease (AD) is the most common neurodegenerative disorder to date.
Neuropathological hallmarks are β‐amyloid (Aβ) plaques and neurofibrillary tangles, but the …

Alzheimer's disease is the most common cause of dementia in elderly people. Research into
Alzheimer's disease therapy has been at least partly successful in terms of developing …

The physiological role of the neurotrophin nerve growth factor (NGF) has been
characterized, since its discovery in the 1950s, first in the sensory and autonomic nervous …

Since its discovery, nerve growth factor (NGF) has long occupied a critical role in
developmental and adult neurobiology for its many important regulatory functions on the …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with
abnormal protein modification, inflammation and memory impairment. Aggregated amyloid …

Nanoparticles (NP) are solid colloidal particles ranging in size from 1 to 1000 nm that are
utilized as drug delivery agents. The use of NPs to deliver drugs to the brain across the …

Current approved drug treatments for Alzheimer disease (AD) include cholinesterase
inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist …